Daily Stock Analysis, NOVN, Novan Inc, priceseries

Novan Inc. Daily Stock Analysis
Stock Information
Open
0.67
Close
0.64
High
0.68
Low
0.64
Previous Close
0.61
Daily Price Gain
0.03
YTD High
3.20
YTD High Date
Jan 2, 2020
YTD Low
0.21
YTD Low Date
Feb 28, 2020
YTD Price Change
-2.47
YTD Gain
-79.29%
52 Week High
3.72
52 Week High Date
Dec 26, 2019
52 Week Low
0.21
52 Week Low Date
Feb 28, 2020
52 Week Price Change
-1.91
52 Week Gain
-74.75%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 15. 2017
6.44
Feb 16. 2017
6.83
1 Trading Days
6.06%
Link
LONG
Jul 26. 2017
4.17
Aug 2. 2017
4.65
5 Trading Days
11.47%
Link
LONG
Aug 24. 2017
4.17
Sep 7. 2017
4.47
9 Trading Days
7.27%
Link
LONG
Oct 19. 2017
5.32
Nov 6. 2017
5.80
12 Trading Days
9.00%
Link
LONG
Jan 2. 2019
0.98
Jan 14. 2019
1.30
8 Trading Days
32.84%
Link
LONG
May 30. 2019
2.23
Jun 10. 2019
2.57
7 Trading Days
15.08%
Link
LONG
Sep 5. 2019
2.50
Sep 24. 2019
2.72
13 Trading Days
8.98%
Link
Company Information
Stock Symbol
NOVN
Exchange
NasdaqGM
Company URL
http://www.novan.com
Company Phone
919-485-8080
CEO
Nathan Stasko
Headquarters
North Carolina
Business Address
4105 HOPSON ROAD, MORRISVILLE, NC 27560
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001467154
About

Novan, Inc. is a late-stage pharmaceutical company, which focuses on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the it's nitric oxide platform. It has two key components of nitric oxide platform: Proprietary Nitricil Technology and Topical Formulation Science. The Proprietary Nitricil Technology drives the creation of new chemical entities. The Topical Formulation Science use to modulate or tune product candidates for specific indications. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Description

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. Novan, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.